Key result
Selective KATP openers match first-generation agents for cardioprotection with less vasorelaxation in animal ischemia models.
Why the study?
KATP openers have demonstrated cardioprotective effects but their use is limited by complications such as coronary steal and hypotension, necessitating development of safer agents.
Do selective KATP openers provide cardioprotection with fewer vasorelaxant side effects in myocardial ischemia?
Do selective KATP openers provide cardioprotection with fewer vasorelaxant side effects in myocardial ischemia?
Selective KATP openers like BMS-180448 may offer a higher margin of safety for cardioprotection during myocardial ischemia by minimizing hypotensive and coronary steal effects.
No takes yet. Share an insight, caveat, or question.
Requires careful risk-benefit assessment before clinical cardioprotection; leaves open safer KATP modulators in human ischemia models.
Atwal et al. (1996) conducted a review in Myocardial Ischemia. ATP-Sensitive Potassium Channel (KATP) Openers vs. First generation agents (e.g., cromakalim) was evaluated. Selective KATP openers like BMS-180448 demonstrated equipotent cardioprotective effects with lower vasorelaxant potencies compared to first-generation agents in animal models of myocardial ischemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: